GLP-1 drugs, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), initially developed for type 2 diabetes, are gaining attention for a wider range of potential health benefits beyond weight loss. Recent data indicates these medications may also positively impact conditions such as sleep apnea, kidney disease, liver conditions, and cardiovascular health.

While the obesity rate in the U.S. remained largely unchanged between 2013 and 2023 according to CDC measurements, a Gallup report from July indicated a decrease in self-reported obesity rates to 36.4 percent in 2022, coinciding with an increase in the use of GLP-1 drugs for weight loss. This observed correlation, though not causal, suggests a potential link between the rise of these medications and shifts in weight trends.

Addressing Diverse Health Conditions

Beyond their effects on appetite and weight, GLP-1s are showing promise in clinical trials for several other health issues:

  • Sleep Apnea: Two year-long trials involving tirzepatide demonstrated that participants experienced more than a 50 percent reduction in breathing interruptions during sleep. Approximately half of the participants achieved results so significant that they no longer experienced daytime fatigue.
  • Kidney Disease: A large trial following over 3,500 individuals with type 2 diabetes and chronic kidney disease found that semaglutide reduced the risk of kidney failure, significant kidney function loss, or kidney-related death by 24 percent. The overall mortality rate in this group was also 20 percent lower.
  • Liver Health: An ongoing trial examining 800 individuals with fatty, inflamed, or scarred livers showed that 72 weeks of semaglutide treatment led to the clearing of inflammation in nearly 63 percent of participants, compared to 34 percent in the placebo group.
  • Osteoarthritis: In a study of 407 adults with obesity and knee osteoarthritis, pain scores decreased by 41.7 points on the WOMAC metric for those on the medication, versus 27.5 points for the placebo group.
  • Cardiovascular Events: A trial involving over 17,600 overweight or obese participants without diabetes reported a 20 percent reduction in major cardiovascular events.

Historical Precedents and Ongoing Concerns

These discoveries echo historical